知镜 Cognispect · 医学文献与研究工作台

Long-term cardiovascular risk in survivors of hematologic malignancies: a meta-analysis.

Liu S, Liu S, Hu Y, Deng J, Sun G, Fang X.
BMC cancer · 2026-06-22 · PMID 42332608

文献摘要

Background The survival rate for hematologic malignancies is steadily improving. With the encouraging trend and the aging of these survivors, there is an ever-increasing responsibility for identifying adverse cardiovascular outcomes associated with carcinogenesis and/or anti-cancer therapies across the span of their lives. However, prospective studies have yielded inconsistent results. Methods We performed a meta-analysis to summarize the evidence regarding the association between leukemia, Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) in relation to later risk of cardiovascular disease (CVD). Relevant literatures were identified from PubMed and Web of Science databases through May 2024 and reviewing reference lists of retrieved articles. Results From the 2412 studies screened, we included 50 studies with 550,385 participants, spanning 1940-2020 for leukemia and 1940-2016 for both Hodgkin and non-Hodgkin lymphoma. The pooled fully adjusted RRs of total CVD, ischemic heart disease (IHD), heart failure (HF), and stroke associated with leukemia were 2.68 (95% confidence interval: 2.22-3.25), 1.46 (1.25-1.70), 4.13 (2.41-7.06), and 3.05 (2.16-4.32), respectively. For HL or NHL survivors, similar positive associations were observed in our study. In addition, compared with survivors with chemotherapy (2.12; 1.89-2.38), radiotherapy-treated survivors had a greater risk of CVD (4.06; 2.84-5.81). Conclusions In summary, survivors of hematologic malignancies, especially those who receive radiotherapy, are at highest risk of developing CVD, emphasizing the need for targeted prevention strategies.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。